ArticleCureus2024
Plasma Exchange as a Viable Therapeutic Option in a Patient With Alcohol-Related Acute-on-Chronic Liver Failure: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute-on-chronic liver failure (ACLF) is a severe form of chronic liver disease associated with multi-system organ dysfunction and high short-term mortality. High-volume plasma exchange (PLEX) is one of the therapeutic measures that improves prognosis. We present the case of a 32-year-old man with alcohol-related liver disease who was admitted with acute decompensation, including coagulopathy, hepatic encephalopathy, and acute kidney injury precipitated by alcoholic hepatitis. Despite standard medical treatment, the inflammatory state did not improve. High-volume PLEX was initiated, and five cycles were completed following a multidisciplinary discussion. This intervention improved the clinical and biochemical status of the patient. Pathologically, ACLF is characterized by systemic inflammation, with high levels of cytokines released into the circulation leading to organ failure. In resource-limited settings where liver transplantation is not available, PLEX is emerging as a promising modality, offering biochemical improvement and enhanced survival. PLEX works by eliminating accumulated toxins in ACLF, aiding the recovery of the failing liver and creating a suitable environment for liver regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.